Gilead’s new capsid inhibitor GS-6207 has started its phase 1b trial with the potential for 3 month dosing. The capsid inhibitor is currently being dosed by a subcutaneous injection but Gilead is attempting to develop a oral formulation of the antiretroviral.
Category: NTIDC News
At the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a second case of an HIV positive adult cleared of the HIV virus after he received a bone marrow transplant from an HIV resistant donor was presented.
At the 2019 Conference on Retroviruses and Opportunistic Infections (CROI), the ATLAS and FLAIR study presented the Phase 3 findings of the Dual Therapy Cabotegravir and Rilpivirine (CAB+RVP) Long-Acting Injection trial.